The litigation surrounding GLP-1 receptor agonists (GLP-1 RA), including Ozempic and Wegovy, represents a significant chapter in the ongoing scrutiny of pharmaceutical safety and marketing ethics. Stemming from allegations that severe gastrointestinal side effects...
